Work

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

Year: 2010

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: The Lancet Neurology

DOI: 10.1016/s1474-4422(10)70033-8

Authors: Daniel Wynn, Michael Kaufman, Xavier Montalban, Timothy Vollmer, Jack Simon, Jacob Elkins, Gilmore O'Neill, Lauri Neyer, James Sheridan, Chungchi Wang, Alice Fong, John W Rose

Institutions: Consultants in Neurology, Carolinas Medical Center, Vall d'Hebron Hospital Universitari, University of Colorado Health, University of Colorado Denver, Biogen (United States), AbbVie Biotherapeutics (United States), University of Utah

Language: English

Topic: Multiple Sclerosis Research Studies

Subfield: Clinical Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Acorda Therapeutics

OpenAlex ID: W2114942536

FWCI: 27.79

Cites: 24

Cited by: 304

Related to: 9